A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: A double-blinded, placebo-controlled trial

Leslie Baumann, Anele Slezinger, Justin Vujevich, Monica Halem, Joy Bryde, Laura Black, Robert Duncan

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Crow's feet develop with age and are one of the earliest signs of the normal aging process. Botulinum toxin type A, approved by the Food and Drug Administration for the treatment of glabellar wrinkles in April 2002, has been used off-label to treat facial wrinkles since 1981. Botulinum toxin type B (BTXB, Myobloc) was Food and Drug Administration-approved for use in cervical dystonia in the United States in December 2000 and has subsequently been used in an off-label indication to treat facial wrinkles. There are sparse data in the literature evaluating the safety and efficacy of BTX-B for the treatment of facial wrinkles. In this pilot study, participants with moderate or severe crow's feet wrinkles were treated with Myobloc versus placebo. The duration of correction and side effect profile are reported.

Original languageEnglish
Pages (from-to)508-515
Number of pages8
JournalDermatologic Surgery
Volume29
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Crows
Neurotoxins
Foot
Placebos
United States Food and Drug Administration
Safety
Torticollis
Type A Botulinum Toxins
Therapeutics
rimabotulinumtoxinB

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet : A double-blinded, placebo-controlled trial. / Baumann, Leslie; Slezinger, Anele; Vujevich, Justin; Halem, Monica; Bryde, Joy; Black, Laura; Duncan, Robert.

In: Dermatologic Surgery, Vol. 29, No. 5, 01.05.2003, p. 508-515.

Research output: Contribution to journalArticle

@article{807d9e77015745df82179e64abbcd4a7,
title = "A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: A double-blinded, placebo-controlled trial",
abstract = "Crow's feet develop with age and are one of the earliest signs of the normal aging process. Botulinum toxin type A, approved by the Food and Drug Administration for the treatment of glabellar wrinkles in April 2002, has been used off-label to treat facial wrinkles since 1981. Botulinum toxin type B (BTXB, Myobloc) was Food and Drug Administration-approved for use in cervical dystonia in the United States in December 2000 and has subsequently been used in an off-label indication to treat facial wrinkles. There are sparse data in the literature evaluating the safety and efficacy of BTX-B for the treatment of facial wrinkles. In this pilot study, participants with moderate or severe crow's feet wrinkles were treated with Myobloc versus placebo. The duration of correction and side effect profile are reported.",
author = "Leslie Baumann and Anele Slezinger and Justin Vujevich and Monica Halem and Joy Bryde and Laura Black and Robert Duncan",
year = "2003",
month = "5",
day = "1",
doi = "10.1046/j.1524-4725.2003.29132.x",
language = "English",
volume = "29",
pages = "508--515",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet

T2 - A double-blinded, placebo-controlled trial

AU - Baumann, Leslie

AU - Slezinger, Anele

AU - Vujevich, Justin

AU - Halem, Monica

AU - Bryde, Joy

AU - Black, Laura

AU - Duncan, Robert

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Crow's feet develop with age and are one of the earliest signs of the normal aging process. Botulinum toxin type A, approved by the Food and Drug Administration for the treatment of glabellar wrinkles in April 2002, has been used off-label to treat facial wrinkles since 1981. Botulinum toxin type B (BTXB, Myobloc) was Food and Drug Administration-approved for use in cervical dystonia in the United States in December 2000 and has subsequently been used in an off-label indication to treat facial wrinkles. There are sparse data in the literature evaluating the safety and efficacy of BTX-B for the treatment of facial wrinkles. In this pilot study, participants with moderate or severe crow's feet wrinkles were treated with Myobloc versus placebo. The duration of correction and side effect profile are reported.

AB - Crow's feet develop with age and are one of the earliest signs of the normal aging process. Botulinum toxin type A, approved by the Food and Drug Administration for the treatment of glabellar wrinkles in April 2002, has been used off-label to treat facial wrinkles since 1981. Botulinum toxin type B (BTXB, Myobloc) was Food and Drug Administration-approved for use in cervical dystonia in the United States in December 2000 and has subsequently been used in an off-label indication to treat facial wrinkles. There are sparse data in the literature evaluating the safety and efficacy of BTX-B for the treatment of facial wrinkles. In this pilot study, participants with moderate or severe crow's feet wrinkles were treated with Myobloc versus placebo. The duration of correction and side effect profile are reported.

UR - http://www.scopus.com/inward/record.url?scp=0038286268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038286268&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4725.2003.29132.x

DO - 10.1046/j.1524-4725.2003.29132.x

M3 - Article

C2 - 12752519

AN - SCOPUS:0038286268

VL - 29

SP - 508

EP - 515

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 5

ER -